Rare disease education in Europe and beyond: time to act
- PMID: 36536417
- PMCID: PMC9761619
- DOI: 10.1186/s13023-022-02527-y
Rare disease education in Europe and beyond: time to act
Abstract
People living with rare diseases (PLWRD) still face huge unmet needs, in part due to the fact that care systems are not sufficiently aligned with their needs and healthcare workforce (HWF) along their care pathways lacks competencies to efficiently tackle rare disease-specific challenges. Level of rare disease knowledge and awareness among the current and future HWF is insufficient. In recent years, many educational resources on rare diseases have been developed, however, awareness of these resources is still limited and rare disease education is still not sufficiently taken into account by some crucial stakeholders as academia and professional organizations. Therefore, there is a need to fundamentally rethink rare disease education and HWF development across the whole spectrum from students to generalists, specialists and experts, to engage and empower PLWRD, their families and advocates, and to work towards a common coherent and complementary strategy on rare disease education and training in Europe and beyond. Special consideration should be also given to the role of nurse coordinators in care coordination, interprofessional training for integrated multidisciplinary care, patient and family-centered education, opportunities given by digital learning and fostering of social accountability to enforce the focus on socially-vulnerable groups such as PLWRD. The strategy has to be developed and implemented by multiple rare disease education and training providers: universities, medical and nursing schools and their associations, professional organizations, European Reference Networks, patient organizations, other organizations and institutions dedicated to rare diseases and rare cancers, authorities and policy bodies.
Keywords: Highly-specialized knowledge; Interprofessional learning; Medical education and training; Patient empowerment; People living with rare disorders; Rare disease awareness; Social accountability.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures

Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Identification of strengths and weaknesses of the healthcare system for persons living with rare diseases in Catalonia (Spain), and recommendations to improve its comprehensive attention: the "acERca las enfermedades raras" project.Orphanet J Rare Dis. 2025 Jan 29;20(1):42. doi: 10.1186/s13023-024-03518-x. Orphanet J Rare Dis. 2025. PMID: 39875900 Free PMC article.
-
Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.Geriatr Gerontol Int. 2015 Jun;15(6):673-87. doi: 10.1111/ggi.12450. Epub 2015 Feb 5. Geriatr Gerontol Int. 2015. PMID: 25656311
-
The management of rare disease patients from a grassroot perspective: the role of patients' organizations in the global recognition of rare diseases in Cameroon.Pan Afr Med J. 2024 Feb 13;47:64. doi: 10.11604/pamj.2024.47.64.38226. eCollection 2024. Pan Afr Med J. 2024. PMID: 38681114 Free PMC article.
-
Bridging the Gap between Health and Social Care for Rare Diseases: Key Issues and Innovative Solutions.Adv Exp Med Biol. 2017;1031:605-627. doi: 10.1007/978-3-319-67144-4_32. Adv Exp Med Biol. 2017. PMID: 29214594 Review.
Cited by
-
Educational needs in diagnosing rare diseases: A multinational, multispecialty clinician survey.Genet Med Open. 2023 Apr 17;1(1):100808. doi: 10.1016/j.gimo.2023.100808. eCollection 2023. Genet Med Open. 2023. PMID: 39669242 Free PMC article.
-
Barriers to and Facilitators of Providing Care for Adolescents Suffering from Rare Diseases: A Mixed Systematic Review.Pediatr Rep. 2023 Aug 9;15(3):462-482. doi: 10.3390/pediatric15030043. Pediatr Rep. 2023. PMID: 37606447 Free PMC article. Review.
-
Policy analysis in the field of rare diseases in China: a combined study of content analysis and Bibliometrics analysis.Front Med (Lausanne). 2023 May 5;10:1180550. doi: 10.3389/fmed.2023.1180550. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37215703 Free PMC article.
-
Unlocking the potential of genetic research in pulmonary arterial hypertension: Insights from clinicians, researchers, and study team.Pulm Circ. 2024 Mar 12;14(1):e12353. doi: 10.1002/pul2.12353. eCollection 2024 Jan. Pulm Circ. 2024. PMID: 38482173 Free PMC article.
-
Barriers to the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.J Clin Endocrinol Metab. 2025 Jan 21;110(Supplement_1):S67-S73. doi: 10.1210/clinem/dgae710. J Clin Endocrinol Metab. 2025. PMID: 39836619 Free PMC article. Review.
References
-
- Orphan Drug Act of 1983. Pub L. No. 97–414, 96 Stat. 2049.
-
- European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the council of 16 December 1999 on orphan medicinal products. 2000. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=LEGISSUM%3Al21167. Accessed 15 Nov 2021.
-
- Adachi T, Imanishi N, Ogawa Y, Furusawa Y, Izumida Y, Izumi Y, et al. Survey on patients with undiagnosed diseases in Japan: potential patient numbers benefiting from 15Japan's initiative on rare and undiagnosed diseases (IRUD) Orphanet J Rare Dis. 2018;13(1):208. doi: 10.1186/s13023-018-0943-y. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical